Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q1 Revenues Rise 2 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today reported that its first-quarter 2011 revenues increased 2 percent as increased sales for its clinical labs business offset lower revenues for its life sciences unit.

The New York-based research products and testing firm brought in total revenues of $25.7 million for the three-month period ended Oct. 31, compared to revenues of $25.2 million for the first quarter of fiscal 2010.

Revenues for the Enzo Clinical Labs jumped 12 percent year over year to $12.4 million from $11.1 million, while product revenues, royalties, and license fees for Enzo Life Sciences declined 6 percent to $13.3 million from $14.1 million.

Enzo Biochem's net loss fell to $1.1 million, or $.03 per share, from $1.8 million, or $.05 per share, year over year.

The firm's R&D spending for Q1 was down 28 percent to $1.8 million, and its SG&A spending decreased 4 percent to $11 million.

Enzo finished the quarter with $31.6 million in cash, cash equivalents, and short-term investments.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.